CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: MACULAR DEGENERATION TREATMENT MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Dry Age Related Macular Degeneration
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Wet Age-Related Macular Degeneration
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
CHAPTER 5: MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE
5.1. Market Overview
5.1.1 Market Size and Forecast, By Stage Of Disease
5.2. Early Stage AMD
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Intermediate Stage AMD
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Late Stage AMD
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Route Of Administration
6.2. Intravenous
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Intravitreal
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
CHAPTER 7: MACULAR DEGENERATION TREATMENT MARKET, BY END USER
7.1. Market Overview
7.1.1 Market Size and Forecast, By End User
7.2. Hospitals And Clinics
7.2.1. Key Market Trends, Growth Factors and Opportunities
7.2.2. Market Size and Forecast, By Region
7.2.3. Market Share Analysis, By Country
7.3. Ambulatory Surgical Center
7.3.1. Key Market Trends, Growth Factors and Opportunities
7.3.2. Market Size and Forecast, By Region
7.3.3. Market Share Analysis, By Country
7.4. Others
7.4.1. Key Market Trends, Growth Factors and Opportunities
7.4.2. Market Size and Forecast, By Region
7.4.3. Market Share Analysis, By Country
CHAPTER 8: MACULAR DEGENERATION TREATMENT MARKET, BY REGION
8.1. Market Overview
8.1.1 Market Size and Forecast, By Region
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, By Type
8.2.3. Market Size and Forecast, By Stage Of Disease
8.2.4. Market Size and Forecast, By Route Of Administration
8.2.5. Market Size and Forecast, By End User
8.2.6. Market Size and Forecast, By Country
8.2.7. U.S. Macular Degeneration Treatment Market
8.2.7.1. Market Size and Forecast, By Type
8.2.7.2. Market Size and Forecast, By Stage Of Disease
8.2.7.3. Market Size and Forecast, By Route Of Administration
8.2.7.4. Market Size and Forecast, By End User
8.2.8. Canada Macular Degeneration Treatment Market
8.2.8.1. Market Size and Forecast, By Type
8.2.8.2. Market Size and Forecast, By Stage Of Disease
8.2.8.3. Market Size and Forecast, By Route Of Administration
8.2.8.4. Market Size and Forecast, By End User
8.2.9. Mexico Macular Degeneration Treatment Market
8.2.9.1. Market Size and Forecast, By Type
8.2.9.2. Market Size and Forecast, By Stage Of Disease
8.2.9.3. Market Size and Forecast, By Route Of Administration
8.2.9.4. Market Size and Forecast, By End User
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, By Type
8.3.3. Market Size and Forecast, By Stage Of Disease
8.3.4. Market Size and Forecast, By Route Of Administration
8.3.5. Market Size and Forecast, By End User
8.3.6. Market Size and Forecast, By Country
8.3.7. France Macular Degeneration Treatment Market
8.3.7.1. Market Size and Forecast, By Type
8.3.7.2. Market Size and Forecast, By Stage Of Disease
8.3.7.3. Market Size and Forecast, By Route Of Administration
8.3.7.4. Market Size and Forecast, By End User
8.3.8. Germany Macular Degeneration Treatment Market
8.3.8.1. Market Size and Forecast, By Type
8.3.8.2. Market Size and Forecast, By Stage Of Disease
8.3.8.3. Market Size and Forecast, By Route Of Administration
8.3.8.4. Market Size and Forecast, By End User
8.3.9. Italy Macular Degeneration Treatment Market
8.3.9.1. Market Size and Forecast, By Type
8.3.9.2. Market Size and Forecast, By Stage Of Disease
8.3.9.3. Market Size and Forecast, By Route Of Administration
8.3.9.4. Market Size and Forecast, By End User
8.3.10. Spain Macular Degeneration Treatment Market
8.3.10.1. Market Size and Forecast, By Type
8.3.10.2. Market Size and Forecast, By Stage Of Disease
8.3.10.3. Market Size and Forecast, By Route Of Administration
8.3.10.4. Market Size and Forecast, By End User
8.3.11. UK Macular Degeneration Treatment Market
8.3.11.1. Market Size and Forecast, By Type
8.3.11.2. Market Size and Forecast, By Stage Of Disease
8.3.11.3. Market Size and Forecast, By Route Of Administration
8.3.11.4. Market Size and Forecast, By End User
8.3.12. Rest Of Europe Macular Degeneration Treatment Market
8.3.12.1. Market Size and Forecast, By Type
8.3.12.2. Market Size and Forecast, By Stage Of Disease
8.3.12.3. Market Size and Forecast, By Route Of Administration
8.3.12.4. Market Size and Forecast, By End User
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, By Type
8.4.3. Market Size and Forecast, By Stage Of Disease
8.4.4. Market Size and Forecast, By Route Of Administration
8.4.5. Market Size and Forecast, By End User
8.4.6. Market Size and Forecast, By Country
8.4.7. China Macular Degeneration Treatment Market
8.4.7.1. Market Size and Forecast, By Type
8.4.7.2. Market Size and Forecast, By Stage Of Disease
8.4.7.3. Market Size and Forecast, By Route Of Administration
8.4.7.4. Market Size and Forecast, By End User
8.4.8. Japan Macular Degeneration Treatment Market
8.4.8.1. Market Size and Forecast, By Type
8.4.8.2. Market Size and Forecast, By Stage Of Disease
8.4.8.3. Market Size and Forecast, By Route Of Administration
8.4.8.4. Market Size and Forecast, By End User
8.4.9. India Macular Degeneration Treatment Market
8.4.9.1. Market Size and Forecast, By Type
8.4.9.2. Market Size and Forecast, By Stage Of Disease
8.4.9.3. Market Size and Forecast, By Route Of Administration
8.4.9.4. Market Size and Forecast, By End User
8.4.10. South Korea Macular Degeneration Treatment Market
8.4.10.1. Market Size and Forecast, By Type
8.4.10.2. Market Size and Forecast, By Stage Of Disease
8.4.10.3. Market Size and Forecast, By Route Of Administration
8.4.10.4. Market Size and Forecast, By End User
8.4.11. Australia Macular Degeneration Treatment Market
8.4.11.1. Market Size and Forecast, By Type
8.4.11.2. Market Size and Forecast, By Stage Of Disease
8.4.11.3. Market Size and Forecast, By Route Of Administration
8.4.11.4. Market Size and Forecast, By End User
8.4.12. Rest of Asia-Pacific Macular Degeneration Treatment Market
8.4.12.1. Market Size and Forecast, By Type
8.4.12.2. Market Size and Forecast, By Stage Of Disease
8.4.12.3. Market Size and Forecast, By Route Of Administration
8.4.12.4. Market Size and Forecast, By End User
8.5. LAMEA
8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, By Type
8.5.3. Market Size and Forecast, By Stage Of Disease
8.5.4. Market Size and Forecast, By Route Of Administration
8.5.5. Market Size and Forecast, By End User
8.5.6. Market Size and Forecast, By Country
8.5.7. Brazil Macular Degeneration Treatment Market
8.5.7.1. Market Size and Forecast, By Type
8.5.7.2. Market Size and Forecast, By Stage Of Disease
8.5.7.3. Market Size and Forecast, By Route Of Administration
8.5.7.4. Market Size and Forecast, By End User
8.5.8. South Africa Macular Degeneration Treatment Market
8.5.8.1. Market Size and Forecast, By Type
8.5.8.2. Market Size and Forecast, By Stage Of Disease
8.5.8.3. Market Size and Forecast, By Route Of Administration
8.5.8.4. Market Size and Forecast, By End User
8.5.9. Saudi Arabia Macular Degeneration Treatment Market
8.5.9.1. Market Size and Forecast, By Type
8.5.9.2. Market Size and Forecast, By Stage Of Disease
8.5.9.3. Market Size and Forecast, By Route Of Administration
8.5.9.4. Market Size and Forecast, By End User
8.5.10. UAE Macular Degeneration Treatment Market
8.5.10.1. Market Size and Forecast, By Type
8.5.10.2. Market Size and Forecast, By Stage Of Disease
8.5.10.3. Market Size and Forecast, By Route Of Administration
8.5.10.4. Market Size and Forecast, By End User
8.5.11. Rest of LAMEA Macular Degeneration Treatment Market
8.5.11.1. Market Size and Forecast, By Type
8.5.11.2. Market Size and Forecast, By Stage Of Disease
8.5.11.3. Market Size and Forecast, By Route Of Administration
8.5.11.4. Market Size and Forecast, By End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping Of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. REGENXBIO Inc.
10.1.1. Company Overview
10.1.2. Key Executives
10.1.3. Company Snapshot
10.1.4. Operating Business Segments
10.1.5. Product Portfolio
10.1.6. Business Performance
10.1.7. Key Strategic Moves and Developments
10.2. Regeneron
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Operating Business Segments
10.2.5. Product Portfolio
10.2.6. Business Performance
10.2.7. Key Strategic Moves and Developments
10.3. Panoptica
10.3.1. Company Overview
10.3.2. Key Executives
10.3.3. Company Snapshot
10.3.4. Operating Business Segments
10.3.5. Product Portfolio
10.3.6. Business Performance
10.3.7. Key Strategic Moves and Developments
10.4. Novartis AG
10.4.1. Company Overview
10.4.2. Key Executives
10.4.3. Company Snapshot
10.4.4. Operating Business Segments
10.4.5. Product Portfolio
10.4.6. Business Performance
10.4.7. Key Strategic Moves and Developments
10.5. Bausch Health Companies Inc
10.5.1. Company Overview
10.5.2. Key Executives
10.5.3. Company Snapshot
10.5.4. Operating Business Segments
10.5.5. Product Portfolio
10.5.6. Business Performance
10.5.7. Key Strategic Moves and Developments
10.6. Pfizer Inc.
10.6.1. Company Overview
10.6.2. Key Executives
10.6.3. Company Snapshot
10.6.4. Operating Business Segments
10.6.5. Product Portfolio
10.6.6. Business Performance
10.6.7. Key Strategic Moves and Developments
10.7. F. Hoffmann-La Roche AG
10.7.1. Company Overview
10.7.2. Key Executives
10.7.3. Company Snapshot
10.7.4. Operating Business Segments
10.7.5. Product Portfolio
10.7.6. Business Performance
10.7.7. Key Strategic Moves and Developments
10.8. Astellas Pharma Inc.
10.8.1. Company Overview
10.8.2. Key Executives
10.8.3. Company Snapshot
10.8.4. Operating Business Segments
10.8.5. Product Portfolio
10.8.6. Business Performance
10.8.7. Key Strategic Moves and Developments
10.9. Thermo Fischer Scientific, Inc.
10.9.1. Company Overview
10.9.2. Key Executives
10.9.3. Company Snapshot
10.9.4. Operating Business Segments
10.9.5. Product Portfolio
10.9.6. Business Performance
10.9.7. Key Strategic Moves and Developments
10.10. Aerie Pharmaceutical Inc.
10.10.1. Company Overview
10.10.2. Key Executives
10.10.3. Company Snapshot
10.10.4. Operating Business Segments
10.10.5. Product Portfolio
10.10.6. Business Performance
10.10.7. Key Strategic Moves and Developments
LIST OF TABLES
Table 1. Global Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 2. Macular Degeneration Treatment Market for Dry Age Related Macular Degeneration, by Region, 2024 - 2033 ($Billion)
Table 3. Macular Degeneration Treatment Market for Wet Age-Related Macular Degeneration, by Region, 2024 - 2033 ($Billion)
Table 4. Global Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 5. Macular Degeneration Treatment Market for Early Stage Amd, by Region, 2024 - 2033 ($Billion)
Table 6. Macular Degeneration Treatment Market for Intermediate Stage Amd, by Region, 2024 - 2033 ($Billion)
Table 7. Macular Degeneration Treatment Market for Late Stage Amd, by Region, 2024 - 2033 ($Billion)
Table 8. Global Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 9. Macular Degeneration Treatment Market for Intravenous, by Region, 2024 - 2033 ($Billion)
Table 10. Macular Degeneration Treatment Market for Intravitreal, by Region, 2024 - 2033 ($Billion)
Table 11. Global Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 12. Macular Degeneration Treatment Market for Hospitals and Clinics, by Region, 2024 - 2033 ($Billion)
Table 13. Macular Degeneration Treatment Market for Ambulatory Surgical Center, by Region, 2024 - 2033 ($Billion)
Table 14. Macular Degeneration Treatment Market for Others, by Region, 2024 - 2033 ($Billion)
Table 15. Macular Degeneration Treatment Market, by Region, 2024 - 2033 ($Billion)
Table 16. North America Macular Degeneration Treatment Market, by Country, 2024 - 2033 ($Billion)
Table 17. North America Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 18. North America Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 19. North America Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 20. North America Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 21. U.S. Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 22. U.S. Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 23. U.S. Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 24. U.S. Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 25. Canada Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 26. Canada Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 27. Canada Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 28. Canada Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 29. Mexico Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 30. Mexico Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 31. Mexico Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 32. Mexico Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 33. Europe Macular Degeneration Treatment Market, by Country, 2024 - 2033 ($Billion)
Table 34. Europe Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 35. Europe Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 36. Europe Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 37. Europe Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 38. France Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 39. France Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 40. France Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 41. France Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 42. Germany Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 43. Germany Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 44. Germany Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 45. Germany Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 46. Italy Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 47. Italy Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 48. Italy Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 49. Italy Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 50. Spain Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 51. Spain Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 52. Spain Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 53. Spain Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 54. UK Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 55. UK Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 56. UK Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 57. UK Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 58. Rest of Europe Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 59. Rest of Europe Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 60. Rest of Europe Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 61. Rest of Europe Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 62. Asia-Pacific Macular Degeneration Treatment Market, by Country, 2024 - 2033 ($Billion)
Table 63. Asia-Pacific Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 64. Asia-Pacific Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 65. Asia-Pacific Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 66. Asia-Pacific Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 67. China Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 68. China Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 69. China Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 70. China Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 71. Japan Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 72. Japan Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 73. Japan Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 74. Japan Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 75. India Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 76. India Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 77. India Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 78. India Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 79. South Korea Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 80. South Korea Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 81. South Korea Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 82. South Korea Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 83. Australia Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 84. Australia Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 85. Australia Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 86. Australia Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 87. Rest of Asia-Pacific Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 88. Rest of Asia-Pacific Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 89. Rest of Asia-Pacific Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 90. Rest of Asia-Pacific Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 91. LAMEA Macular Degeneration Treatment Market, by Country, 2024 - 2033 ($Billion)
Table 92. LAMEA Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 93. LAMEA Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 94. LAMEA Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 95. LAMEA Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 96. Brazil Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 97. Brazil Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 98. Brazil Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 99. Brazil Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 100. South Africa Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 101. South Africa Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 102. South Africa Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 103. South Africa Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 104. Saudi Arabia Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 105. Saudi Arabia Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 106. Saudi Arabia Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 107. Saudi Arabia Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 108. UAE Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 109. UAE Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 110. UAE Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 111. UAE Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 112. Rest of LAMEA Macular Degeneration Treatment Market, by Type, 2024 - 2033 ($Billion)
Table 113. Rest of LAMEA Macular Degeneration Treatment Market, by Stage of Disease, 2024 - 2033 ($Billion)
Table 114. Rest of LAMEA Macular Degeneration Treatment Market, by Route of Administration, 2024 - 2033 ($Billion)
Table 115. Rest of LAMEA Macular Degeneration Treatment Market, by End-user, 2024 - 2033 ($Billion)
Table 116. Regenxbio Inc.: Key Executives
Table 117. Regenxbio Inc.: Company Snapshot
Table 118. Regenxbio Inc.: Operating Segments
Table 119. Regenxbio Inc.: Product Portfolio
Table 120. Regenxbio Inc.: Key Strategic Moves and Developments
Table 121. Regeneron: Key Executives
Table 122. Regeneron: Company Snapshot
Table 123. Regeneron: Operating Segments
Table 124. Regeneron: Product Portfolio
Table 125. Regeneron: Key Strategic Moves and Developments
Table 126. Panoptica: Key Executives
Table 127. Panoptica: Company Snapshot
Table 128. Panoptica: Operating Segments
Table 129. Panoptica: Product Portfolio
Table 130. Panoptica: Key Strategic Moves and Developments
Table 131. Novartis AG: Key Executives
Table 132. Novartis AG: Company Snapshot
Table 133. Novartis AG: Operating Segments
Table 134. Novartis AG: Product Portfolio
Table 135. Novartis AG: Key Strategic Moves and Developments
Table 136. Bausch Health Companies Inc.: Key Executives
Table 137. Bausch Health Companies Inc.: Company Snapshot
Table 138. Bausch Health Companies Inc.: Operating Segments
Table 139. Bausch Health Companies Inc.: Product Portfolio
Table 140. Bausch Health Companies Inc.: Key Strategic Moves and Developments
Table 141. Pfizer Inc.: Key Executives
Table 142. Pfizer Inc.: Company Snapshot
Table 143. Pfizer Inc.: Operating Segments
Table 144. Pfizer Inc.: Product Portfolio
Table 145. Pfizer Inc.: Key Strategic Moves and Developments
Table 146. F. Hoffmann-La Roche AG: Key Executives
Table 147. F. Hoffmann-La Roche AG: Company Snapshot
Table 148. F. Hoffmann-La Roche AG: Operating Segments
Table 149. F. Hoffmann-La Roche AG: Product Portfolio
Table 150. F. Hoffmann-La Roche AG: Key Strategic Moves and Developments
Table 151. Astellas Pharma Inc.: Key Executives
Table 152. Astellas Pharma Inc.: Company Snapshot
Table 153. Astellas Pharma Inc.: Operating Segments
Table 154. Astellas Pharma Inc.: Product Portfolio
Table 155. Astellas Pharma Inc.: Key Strategic Moves and Developments
Table 156. Thermo Fischer Scientific, Inc.: Key Executives
Table 157. Thermo Fischer Scientific, Inc.: Company Snapshot
Table 158. Thermo Fischer Scientific, Inc.: Operating Segments
Table 159. Thermo Fischer Scientific, Inc.: Product Portfolio
Table 160. Thermo Fischer Scientific, Inc.: Key Strategic Moves and Developments
Table 161. Aerie Pharmaceutical Inc.: Key Executives
Table 162. Aerie Pharmaceutical Inc.: Company Snapshot
Table 163. Aerie Pharmaceutical Inc.: Operating Segments
Table 164. Aerie Pharmaceutical Inc.: Product Portfolio
Table 165. Aerie Pharmaceutical Inc.: Key Strategic Moves and Developments
LIST OF FIGURES
Figure 1. Global Macular Degeneration Treatment Market, 2024 - 2033
Figure 2. Segmentation of Macular Degeneration Treatment Market, 2024 - 2033
Figure 3. Top Investment Pocket in Macular Degeneration Treatment Market
Figure 4. Moderate Bargaining Power of Buyers
Figure 5. Moderate Bargaining Power of Suppliers
Figure 6. Moderate Threat of New Entrants
Figure 7. Low Threat of Substitution
Figure 8. High Competitive Rivalry
Figure 9. Opportunities, Restraints and Drivers: Globalmacular Degeneration Treatment Market
Figure 10. Global Macular Degeneration Treatment Market Segmentation, by Type
Figure 11. Macular Degeneration Treatment Market for Dry Age Related Macular Degeneration, by Country, 2024 - 2033 ($Billion)
Figure 12. Macular Degeneration Treatment Market for Wet Age-Related Macular Degeneration, by Country, 2024 - 2033 ($Billion)
Figure 13. Global Macular Degeneration Treatment Market Segmentation, by Stage of Disease
Figure 14. Macular Degeneration Treatment Market for Early Stage Amd, by Country, 2024 - 2033 ($Billion)
Figure 15. Macular Degeneration Treatment Market for Intermediate Stage Amd, by Country, 2024 - 2033 ($Billion)
Figure 16. Macular Degeneration Treatment Market for Late Stage Amd, by Country, 2024 - 2033 ($Billion)
Figure 17. Global Macular Degeneration Treatment Market Segmentation, by Route of Administration
Figure 18. Macular Degeneration Treatment Market for Intravenous, by Country, 2024 - 2033 ($Billion)
Figure 19. Macular Degeneration Treatment Market for Intravitreal, by Country, 2024 - 2033 ($Billion)
Figure 20. Global Macular Degeneration Treatment Market Segmentation, by End-user
Figure 21. Macular Degeneration Treatment Market for Hospitals and Clinics, by Country, 2024 - 2033 ($Billion)
Figure 22. Macular Degeneration Treatment Market for Ambulatory Surgical Center, by Country, 2024 - 2033 ($Billion)
Figure 23. Macular Degeneration Treatment Market for Others, by Country, 2024 - 2033 ($Billion)
Figure 24. Top Winning Strategies, by Year, 2021-2023*
Figure 25. Top Winning Strategies, by Development, 2021-2023*
Figure 26. Top Winning Strategies, by Company, 2021-2023*
Figure 27. Product Mapping of Top 10 Players
Figure 28. Competitive Dashboard
Figure 29. Competitive Heatmap: Macular Degeneration Treatment Market
Figure 30. Top Player Positioning, 2023
Figure 31. Regenxbio Inc.: Net Sales, 2021-2023 ($Billion)
Figure 32. Regenxbio Inc.: Revenue Share, by Segment, 2023 (%)
Figure 33. Regenxbio Inc.: Revenue Share, by Region, 2023 (%)
Figure 34. Regeneron: Net Sales, 2021-2023 ($Billion)
Figure 35. Regeneron: Revenue Share, by Segment, 2023 (%)
Figure 36. Regeneron: Revenue Share, by Region, 2023 (%)
Figure 37. Panoptica: Net Sales, 2021-2023 ($Billion)
Figure 38. Panoptica: Revenue Share, by Segment, 2023 (%)
Figure 39. Panoptica: Revenue Share, by Region, 2023 (%)
Figure 40. Novartis AG: Net Sales, 2021-2023 ($Billion)
Figure 41. Novartis AG: Revenue Share, by Segment, 2023 (%)
Figure 42. Novartis AG: Revenue Share, by Region, 2023 (%)
Figure 43. Bausch Health Companies Inc.: Net Sales, 2021-2023 ($Billion)
Figure 44. Bausch Health Companies Inc.: Revenue Share, by Segment, 2023 (%)
Figure 45. Bausch Health Companies Inc.: Revenue Share, by Region, 2023 (%)
Figure 46. Pfizer Inc.: Net Sales, 2021-2023 ($Billion)
Figure 47. Pfizer Inc.: Revenue Share, by Segment, 2023 (%)
Figure 48. Pfizer Inc.: Revenue Share, by Region, 2023 (%)
Figure 49. F. Hoffmann-La Roche AG: Net Sales, 2021-2023 ($Billion)
Figure 50. F. Hoffmann-La Roche AG: Revenue Share, by Segment, 2023 (%)
Figure 51. F. Hoffmann-La Roche AG: Revenue Share, by Region, 2023 (%)
Figure 52. Astellas Pharma Inc.: Net Sales, 2021-2023 ($Billion)
Figure 53. Astellas Pharma Inc.: Revenue Share, by Segment, 2023 (%)
Figure 54. Astellas Pharma Inc.: Revenue Share, by Region, 2023 (%)
Figure 55. Thermo Fischer Scientific, Inc.: Net Sales, 2021-2023 ($Billion)
Figure 56. Thermo Fischer Scientific, Inc.: Revenue Share, by Segment, 2023 (%)
Figure 57. Thermo Fischer Scientific, Inc.: Revenue Share, by Region, 2023 (%)
Figure 58. Aerie Pharmaceutical Inc.: Net Sales, 2021-2023 ($Billion)
Figure 59. Aerie Pharmaceutical Inc.: Revenue Share, by Segment, 2023 (%)
Figure 60. Aerie Pharmaceutical Inc.: Revenue Share, by Region, 2023 (%)
